Trulieve Makes History as First US Cannabis Company on the NYSE

A Landmark Day for Cannabis on Wall Street

When the opening bell rings at the New York Stock Exchange on Tuesday, June 10, 2026, it will mark a moment that cannabis executives, investors, and advocates have been chasing for over a decade. Trulieve Cannabis Corp., the Florida-based multistate operator, will begin trading under the ticker symbol TRLV — becoming the first US plant-touching cannabis company to list on a major American stock exchange.

The milestone is the direct result of the federal regulatory shift that began on April 23, 2026, when Acting Attorney General Todd Blanche issued an order moving FDA-approved marijuana products and qualifying state-licensed medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act. That reclassification didn't just change how the government categorizes cannabis — it unlocked the door to institutional finance.

"This listing was made possible by common sense action by President Trump to reclassify medical marijuana to Schedule III," said Trulieve CEO Kim Rivers in a statement confirming the NYSE approval. Rivers called the uplisting "a watershed moment not just for Trulieve but for the entire legal cannabis industry in the United States."

How Trulieve Structured Its Way Onto the NYSE

Getting onto the NYSE wasn't as simple as filling out an application. Federal securities regulations and exchange listing standards have historically prevented companies that derive revenue from federally illegal activity from trading on major exchanges. Even after Schedule III reclassification, adult-use (recreational) cannabis remains in Schedule I.

Trulieve navigated this by restructuring its corporate operations. The company spun off its adult-use cannabis assets into a separate entity, retaining only its medical cannabis operations — which now fall squarely under the Schedule III framework — in the publicly traded company. This legal architecture satisfied NYSE listing requirements while preserving Trulieve's ability to operate in the broader cannabis market through its subsidiary.

The company's subordinate voting shares were approved for listing after a thorough review process. Trulieve's shares will continue to trade on the Canadian Securities Exchange under TRUL and on the OTCQX under TCNNF until the close of trading on June 9, after which the NYSE listing under TRLV takes over as the primary market.

Why the NYSE Matters More Than You Think

For casual observers, moving from one stock exchange to another might seem like a technical detail. For the cannabis industry, it's transformative.

Trading on a major US exchange unlocks access to institutional capital that has been largely off-limits to cannabis companies. Pension funds, mutual funds, ETFs, and many institutional investors have mandates that restrict them to securities listed on recognized exchanges. When cannabis companies traded exclusively on the Canadian Securities Exchange or US over-the-counter markets, they were effectively invisible to the largest pools of investment capital in the world.

Analyst coverage is another critical benefit. Major Wall Street firms typically don't cover OTC or CSE-listed cannabis stocks. NYSE listing opens the door to research coverage from firms like Goldman Sachs, Morgan Stanley, and JPMorgan — coverage that drives awareness, liquidity, and valuation multiples.

Liquidity itself matters enormously. The NYSE processes billions of dollars in daily trading volume with tight bid-ask spreads. Cannabis stocks on the OTC and CSE have historically suffered from wide spreads, thin volume, and limited price discovery. Moving to the NYSE should compress spreads and make it easier for investors to enter and exit positions.

The Competitive Landscape: Who's Next?

Trulieve is first, but it won't be alone for long. The race to uplist is already underway across the multistate operator landscape.

Verano Holdings announced a 1-for-5 reverse stock split on June 1, 2026, explicitly designed to "advance Verano on its path towards listing its common stock on a major U.S. stock exchange." The consolidation takes effect around June 11 — just one day after Trulieve begins NYSE trading. Curaleaf Holdings announced its own 1-for-3 reverse split earlier this year with similar uplist ambitions.

Green Thumb Industries became the first MSO to file for DEA Schedule III registration, positioning itself for potential exchange listing. The CLIMB Act, currently working through Congress, would explicitly authorize cannabis companies to trade on US exchanges, potentially opening the door even wider.

The competitive dynamic is clear: companies that uplist first gain a structural advantage in accessing institutional capital, potentially at lower costs of capital than rivals stuck on secondary exchanges.

What This Means for Investors

For retail investors who have held cannabis stocks through years of losses, regulatory uncertainty, and exchange limitations, the Trulieve listing represents validation. The cannabis sector has been one of the worst-performing in public markets over the past five years, with many MSOs losing 70-90% of their peak valuations.

The NYSE listing doesn't guarantee a turnaround, but it changes the structural dynamics. Institutional participation tends to reduce volatility, improve price discovery, and provide a more stable shareholder base. The elimination of Section 280E — which previously prevented cannabis companies from deducting ordinary business expenses — has already improved profitability across the sector.

Trulieve reported $287 million in revenue and its first profitable quarter in Q1 2026, a performance directly boosted by 280E relief. The combination of improving fundamentals and major exchange listing could catalyze a rerating of the entire sector.

The Caveats

It's worth noting what the NYSE listing doesn't change. Federal legalization of recreational cannabis remains uncertain. The DEA's administrative hearing beginning June 29 will consider whether to extend Schedule III classification to all marijuana — not just medical products under state licenses — but the outcome is far from guaranteed.

Cannabis companies face ongoing challenges including price compression in mature markets, persistent illicit market competition, and the potential for the Schedule III framework to create a two-tiered industry where medical operators have advantages that recreational-only companies don't.

Additionally, the restructuring Trulieve undertook to separate its medical and adult-use operations adds corporate complexity. Investors will need to understand exactly what assets and revenue streams are included in the NYSE-listed entity versus the spun-off adult-use subsidiary.

The Bigger Picture

Trulieve's NYSE debut isn't just a company milestone — it's an industry inflection point. For years, the cannabis sector has existed in a financial no-man's-land: legal in most states, federally ambiguous, and locked out of the institutions that define mainstream American capitalism.

A cannabis stock trading on the New York Stock Exchange alongside Apple, JPMorgan, and Coca-Cola sends a signal that the era of cannabis as a fringe investment is ending. Whether that signal translates into sustained value creation depends on execution, regulation, and the broader market environment.

But on June 10, 2026, when TRLV flashes across NYSE trading screens for the first time, the cannabis industry will have crossed a threshold it can never uncross. Wall Street is officially open for weed.